Pharmacological correction of a defect in PPAR-γ signaling ameliorates disease severity in Cftr-deficient mice

Nature Medicine

Volumn 16, Issue 3, 2010, Pages 313-318

  Harmon, Gregory S ^a   Dumlao, Darren S ^b   Ng, Damian T ^c   Barrett, Kim E ^a   Dennis, Edward A ^b   Dong, Hui ^a   Glass, Christopher K ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A ACETYLTRANSFERASE; ANGIOPOIETIN; BICARBONATE; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE IV; CHLORIDE; CXCL1 CHEMOKINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2; ROSIGLITAZONE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLON MUCOSA; COLON SECRETION; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE SEVERITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BICARBONATES; CARBONIC ANHYDRASE II; CARBONIC ANHYDRASE IV; COLON; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DINOPROSTONE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED CFTR; PPAR GAMMA; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

MUS;

EID: 77749246086     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2101     Document Type: Article

References (40)

1. O'Sullivan, B.P. & Freedman, S.D. Cystic fbrosis. Lancet 373, 1891-1904 (2009)
2. Zuelzer, W.W. & Newton, W.A. Jr. The pathogenesis of fbrocystic disease of the pancreas; a study of 36 cases with special reference to the pulmonary lesions. Pediatrics 4, 53-69 (1949)
3. Freedman, S.D. et al. Association of cystic fbrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med. 350, 560-569 (2004)
4. Hardin, D.S., LeBlanc, A., Lukenbough, S. & Seilheimer, D.K. Insulin resistance is associated with decreased clinical status in cystic fbrosis. J. Pediatr. 130, 948-956 (1997)
5. Snouwaert, J.N. et al. An animal model for cystic fbrosis made by gene targeting. Science 257, 1083-1088 (1992)
6. Eckman, E.A., Cotton, C.U., Kube, D.M. & Davis, P.B. Dietary changes improve survival of CFTR S489X homozygous mutant mouse. Am. J. Physiol. 269, L625-L630 (1995)
7. Clarke, L.L., Gawenis, L.R., Franklin, C.L. & Harline, M.C. Increased survival of CFTR knockout mice with an oral osmotic laxative. Lab. Anim. Sci. 46, 612-618 (1996)
8. Gene Ontology Consortium. Creating the gene ontology resource: design and implementation. Genome Res. 11, 1425-1433 (2001)
9. -/- mice. J. Cell. Physiol. 200, 235-244 (2004)
10. Yu, S. et al. Human peroxisome proliferator-activated receptor a (PPARa) supports the induction of peroxisome proliferation in PPARa-defcient mouse liver. J. Biol. Chem. 276, 42485-42491 (2001)
11. Tachibana, K. et al. Gene expression profling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms. Nucl. Recept. 3, 3 (2005)
12. Lytle, C. et al. The peroxisome proliferator-activated receptor y ligand rosiglitazone delays the onset of infammatory bowel disease in mice with interleukin 10 defciency. Infamm. Bowel Dis. 11, 231-243 (2005)
13. Madison, B.B. et al. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J. Biol. Chem. 277, 33275-33283 (2002)
14. Adachi, M. et al. Peroxisome proliferator activated receptor y in colonic epithelial cells protects against experimental infammatory bowel disease. Gut 55, 1104-1113 (2006)
15. Hamosh, A., Rosenstein, B.J. & Cutting, G.R. CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells. Hum. Mol. Genet. 1, 542-544 (1992)
16. Zeitlin, P.L. et al. A cystic fbrosis bronchial epithelial cell line: immortalization by adeno-12-SV40 infection. Am. J. Respir. Cell Mol. Biol. 4, 313-319 (1991)
17. 2. Proc. Natl. Acad. Sci. USA 102, 15247-15252 (2005)
18. McMurtrie, H.L. et al. The bicarbonate transport metabolon. J. Enzyme Inhib. Med. Chem. 19, 231-236 (2004)
19. Sellers, Z.M. et al. Heat-stable enterotoxin of Escherichia coli stimulates a non-CFTR-mediated duodenal bicarbonate secretory pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G654-G663 (2005)
20. Rodríguez, J.C., Gil-Gomez, G., Hegardt, F.G. & Haro, D. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J. Biol. Chem. 269, 18767-18772 (1994)
21. Mandard, S. et al. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofbrate treatment. J. Biol. Chem. 279, 34411-34420 (2004)
22. Ge, K. et al. Transcription coactivator TRAP220 is required for PPARy2-stimulated adipogenesis. Nature 417, 563-567 (2002)
23. Yuan, C.X., Ito, M., Fondell, J.D., Fu, Z.Y. & Roeder, R.G. The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. Proc. Natl. Acad. Sci. USA 95, 7939-7944 (1998)
24. Wigren, J. et al. Differential recruitment of the coactivator proteins CREB-binding protein and steroid receptor coactivator-1 to peroxisome proliferator-activated receptor y/9-cis-retinoic acid receptor heterodimers by ligands present in oxidized low-density lipoprotein. J. Endocrinol. 177, 207-214 (2003)
25. 2 catabolism in regulation of peroxisome proliferator-activated receptor y activation. J. Biol. Chem. 282, 18162-18172 (2007)
26. Perez, A. et al. Peroxisome proliferator-activated receptor-y in cystic fbrosis lung epithelium. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L303-L313 (2008)
27. 2 in patients with stable and unstable cystic fbrosis. Free Radic. Biol. Med. 45, 913-919 (2008)
28. Su, C.G. et al. A novel therapy for colitis utilizing PPAR-y ligands to inhibit the epithelial infammatory response. J. Clin. Invest. 104, 383-389 (1999)
29. Lewis, J.D. et al. An open-label trial of the PPAR-y ligand rosiglitazone for active ulcerative colitis. Am. J. Gastroenterol. 96, 3323-3328 (2001)
30. Matsui, H. et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fbrosis airways disease. Cell 95, 1005-1015 (1998)
31. Garcia, M.A., Yang, N. & Quinton, P.M. Normal mouse intestinal mucus release requires cystic fbrosis transmembrane regulator-dependent bicarbonate secretion. J. Clin. Invest. 119, 2613-2622 (2009)
32. Quinton, P.M. Cystic fbrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 372, 415-417 (2008)
33. Nichols, D.P., Konstan, M.W. & Chmiel, J.F. Anti-infammatory therapies for cystic fbrosis-related lung disease. Clin. Rev. Allergy Immunol. 35, 135-153 (2008)
34. Konstan, M.W. et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fbrosis and healthy subjects. J. Pharmacol. Exp. Ther. 306, 1086-1091 (2003)
35. Akiyama, T.E. et al. Conditional disruption of the peroxisome proliferator-activated receptor y gene in mice results in lowered expression of ABCA1, ABCG1 and apoE in macrophages and reduced cholesterol effux. Mol. Cell. Biol. 22, 2607-2619 (2002)
36. Rogler, G. et al. Establishment of long-term primary cultures of human small and large intestinal epithelial cells. Lab. Invest. 78, 889-890 (1998)
37. Ogawa, S. et al. A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation. Proc. Natl. Acad. Sci. USA 101, 14461-14466 (2004)
38. Blaho, V.A., Buczynski, M.W., Brown, C.R. & Dennis, E.A. Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of Lyme arthritis. J. Biol. Chem. 284, 21599-21612 (2009)
39. Zarini, S., Gijon, M.A., Folco, G. & Murphy, R.C. Effect of arachidonic acid reacylation on leukotriene biosynthesis in human neutrophils stimulated with granulocyte-macrophage colony-stimulating factor and formyl-methionyl-leucyl-phenylalanine. J. Biol. Chem. 281, 10134-10142 (2006)
40. Quehenberger, O., Armando, A., Dumlao, D., Stephens, D.L. & Dennis, E.A. Lipidomics analysis of essential fatty acids in macrophages. Prostaglandins Leukot. Essent. Fatty Acids 79, 123-129 (2008)